Xencor Inc
F:XE9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X
|
Xencor Inc
F:XE9
|
US |
|
I
|
Imax Corp
XBER:IMA
|
CA |
|
Fuji Kyuko Co Ltd
F:8V7
|
JP |
|
A
|
ADTRAN Holdings Inc
XMUN:QH9
|
US |
|
K
|
Kohls Corp
BMV:KSS
|
US |
|
Plains GP Holdings LP
NASDAQ:PAGP
|
US |
|
T
|
Tinc Comm VA
F:5TI
|
BE |
|
P
|
Puma SE
XHAM:PUM
|
DE |
|
S
|
Sumitomo Rubber Industries Ltd
SWB:108
|
JP |
|
L
|
LKQ Corp
F:LKQ1
|
US |
|
Kasumigaseki Capital Co Ltd
F:H0A
|
JP |
|
NSD Co Ltd
TSE:9759
|
JP |
|
H
|
HP Inc
XETRA:7HP
|
US |
|
M
|
Mentice AB
STO:MNTC
|
SE |
|
K
|
Kohls Corp
SWB:KHP
|
US |
|
A
|
Amcor PLC
XBER:485
|
UK |
|
G
|
Gold Fields Ltd
JSE:GFI
|
ZA |
|
D
|
Dongfang Electric Corp Ltd
SWB:DEU
|
CN |
|
M
|
Motorola Solutions Inc
XMUN:MTLA
|
US |
|
C
|
Corcept Therapeutics Inc
XBER:HTD
|
US |
|
U
|
UDR Inc
LSE:0LHS
|
US |
|
T
|
Tsingtao Brewery Co Ltd
XBER:TSI
|
CN |
|
Vestas Wind Systems A/S
XETRA:VWSB
|
DK |
|
Danaher Corp
NYSE:DHR
|
US |
Xencor Inc
Xencor is a biotechnology company that designs engineered antibodies and other protein drugs. Its main work is to create drug candidates that can be used on their own or paired with other medicines, especially in cancer and immune diseases. The company earns money by advancing its own drug programs and by licensing its technology to larger drugmakers. Its core technology is the XmAb platform, which changes how antibodies behave so they can target disease more effectively or stay in the body longer. Xencor sells access to that technology through research collaborations, licensing deals, and milestone and royalty payments, while also developing a portfolio of proprietary drug candidates that it can test, partner, or commercialize. Xencor’s customers are mainly pharmaceutical and biotech companies that want to use its antibody engineering tools, along with patients and doctors who may eventually use drugs from its own pipeline. What makes the business different is that it sits in the middle of two models: it is both a drug developer and a technology supplier to the wider biotech industry.
Xencor is a biotechnology company that designs engineered antibodies and other protein drugs. Its main work is to create drug candidates that can be used on their own or paired with other medicines, especially in cancer and immune diseases. The company earns money by advancing its own drug programs and by licensing its technology to larger drugmakers.
Its core technology is the XmAb platform, which changes how antibodies behave so they can target disease more effectively or stay in the body longer. Xencor sells access to that technology through research collaborations, licensing deals, and milestone and royalty payments, while also developing a portfolio of proprietary drug candidates that it can test, partner, or commercialize.
Xencor’s customers are mainly pharmaceutical and biotech companies that want to use its antibody engineering tools, along with patients and doctors who may eventually use drugs from its own pipeline. What makes the business different is that it sits in the middle of two models: it is both a drug developer and a technology supplier to the wider biotech industry.
Pipeline Focus: Xencor is shifting its resources to prioritize T-cell engagers, especially bispecific antibodies for solid tumors, while reducing investment in cytokine drug candidates.
Vudalimab Results: Vudalimab showed encouraging single-agent activity in heavily pre-treated metastatic castration-resistant prostate cancer, with a RECIST response rate of 35% and disease control rate of 50%.
Safety Profile: Vudalimab's safety is consistent with other checkpoint inhibitors, though one Grade 5 immune-related hepatitis case was reported among over 240 treated patients.
Financial Strength: The company ended 2023 with $697 million in cash, expecting its runway to extend into 2027.
Clinical Progress: Multiple Phase I dose-escalation studies are ongoing for new T-cell engagers, and the first frontline lung cancer study for vudalimab has started dosing patients.
Guidance: Xencor expects to enroll 20–30 patients in vudalimab monotherapy and combination cohorts by the first half of next year to inform go/no-go decisions.
